相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Sphingosine 1-Phosphate as Essential Signaling Molecule in Inflammatory Skin Diseases
Burkhard Kleuser et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)
P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials
S Vermeire et al.
Journal of Crohns & Colitis (2023)
DOP37 Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study
S Danese et al.
Journal of Crohns & Colitis (2023)
Probiotic Yeast from Miso Ameliorates Stress-Induced Visceral Hypersensitivity by Modulating the Gut Microbiota in a Rat Model of Irritable Bowel Syndrome
Nao Sugihara et al.
GUT AND LIVER (2023)
European Crohn's and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation
Joana Torres et al.
JOURNAL OF CROHNS & COLITIS (2023)
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
William J. Sandborn et al.
LANCET (2023)
Dietary Sources of Anthocyanins and Their Association with Metabolome Biomarkers and Cardiometabolic Risk Factors in an Observational Study
Hamza Mostafa et al.
NUTRIENTS (2023)
Effects of Diet and Exercise on Circadian Rhythm: Role of Gut Microbiota in Immune and Metabolic Systems
Yidan Cai et al.
NUTRIENTS (2023)
An Assessment of Mushroom Consumption on Cardiometabolic Disease Risk Factors and Morbidities in Humans: A Systematic Review
Cassi N. Uffelman et al.
NUTRIENTS (2023)
Dietary Implications of the Bidirectional Relationship between the Gut Microflora and Inflammatory Diseases with Special Emphasis on Irritable Bowel Disease: Current and Future Perspective
Tariq Aziz et al.
NUTRIENTS (2023)
The effect of higher protein dosing in critically ill patients with high nutritional risk (EFFORT Protein) (vol 401, pg 568, 2023)
D. K. Heyland et al.
LANCET (2023)
POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF OZANIMOD IN ULCERATIVE COLITIS
Daniel Tatosian et al.
GASTROENTEROLOGY (2022)
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
Tim Raine et al.
JOURNAL OF CROHNS & COLITIS (2022)
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease
Bram Verstockt et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2022)
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
Silvio Danese et al.
LANCET (2022)
Human gut microbiota in health and disease: Unveiling the relationship
Muhammad Afzaal et al.
FRONTIERS IN MICROBIOLOGY (2022)
S694 Comparative Efficacy and Safety of Ozanimod vs Adalimumab and Vedolizumab in Patients with Moderately to Severely Active Ulcerative Colitis
Marla C. Dubinsky et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2021)
Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study
Severine Vermeire et al.
JOURNAL OF CROHNS & COLITIS (2021)
Gut microbiota and their metabolites in cardiovascular disease
Valerie LBI. Jansen et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
Brian G. Feagan et al.
LANCET (2021)
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2TOUCHSTONE Study
William J. Sandborn et al.
JOURNAL OF CROHNS & COLITIS (2021)
Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2020)
AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis
Joseph D. Feuerstein et al.
GASTROENTEROLOGY (2020)
Is there a role for therapeutic sphingolipids in inflammatory bowel disease?
Tommaso Lorenzo Parigi et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2020)
Tu1852 PHARMACOKINETICS AND PHARMACODYNAMICS OF OPL-002, A HIGHLY SELECTIVE S1P1R MODULATOR, IN HEALTHY ADULT VOLUNTEERS.
Allison Luo et al.
GASTROENTEROLOGY (2020)
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study
Brian G. Feagan et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Unveiling role of sphingosine-1-phosphate receptor 2 as a brake of epithelial stem cell proliferation and a tumor suppressor in colorectal cancer
Luciana Petti et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Amiselimod, a sphingosine 1-phosphate receptor-1 modulator, for systemic lupus erythematosus: A multicenter, open-label exploratory study
Yoshiya Tanaka et al.
LUPUS (2020)
Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts
Tamara Perez-Jeldres et al.
INFLAMMATORY BOWEL DISEASES (2019)
Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists
Tamara Perez-Jeldres et al.
FRONTIERS IN PHARMACOLOGY (2019)
Interfering with leukocyte trafficking in Crohn's disease
Sujata Biswas et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2019)
Sphingosine-1-Phosphate Receptor Subtype 1 (S1P1) Modulator IMMH001 Regulates Adjuvant- and Collagen-Induced Arthritis
Jing Jin et al.
FRONTIERS IN PHARMACOLOGY (2019)
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
Jeffrey A. Cohen et al.
LANCET NEUROLOGY (2019)
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
Giancarlo Comi et al.
LANCET NEUROLOGY (2019)
Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence
Pablo Olivera et al.
DIGESTIVE AND LIVER DISEASE (2019)
Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease
Amy Hemperly et al.
INFLAMMATORY BOWEL DISEASES (2018)
Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life
Paschalis Paschos et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study
Jonathan Q. Tran et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2018)
Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-I-Phosphate Receptor Modulator
Jonathan Q. Tran et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2018)
Next generation of small molecules in inflammatory bowel disease
Pablo Olivera et al.
GUT (2017)
Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease
T. Karuppuchamy et al.
MUCOSAL IMMUNOLOGY (2017)
JAK inhibition in inflammatory bowel disease
Pablo Olivera et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)
Novel therapeutic targets for inflammatory bowel disease
Marjorie Argollo et al.
JOURNAL OF AUTOIMMUNITY (2017)
Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator
Jonathan Q. Tran et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Modulation of sphingosine-1-phosphate in inflammatory bowel disease
Laurent Peyrin-Biroulet et al.
AUTOIMMUNITY REVIEWS (2017)
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity
F. L. Scott et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators
Pierre-Eric Juif et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
Giulia Roda et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2016)
Bitopic Sphingosine 1-Phosphate Receptor 3 (S1P3) Antagonist Rescue from Complete Heart Block: Pharmacological and Genetic Evidence for Direct S1P3 Regulation of Mouse Cardiac Conduction
M. Germana Sanna et al.
MOLECULAR PHARMACOLOGY (2016)
Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy
Richard L. Proia et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Biologic agents for IBD: practical insights
Silvio Danese et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial
Andrea Vaclavkova et al.
LANCET (2014)
Sphingosine-1-Phosphate and Lymphocyte Egress from Lymphoid Organs
Jason G. Cyster et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 30 (2012)
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Sphingosine 1-phosphate (S1P) Physiology and the effects of S1P receptor modulation
Timothy Hla et al.
NEUROLOGY (2011)
The outs and the ins of sphingosine-1-phosphate in immunity
Sarah Spiegel et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Systematic review: the costs of ulcerative colitis in Western countries
R. D. Cohen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules
David Marsolais et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
"Inside-Out" Signaling of Sphingosine-1-Phosphate: Therapeutic Targets
K. Takabe et al.
PHARMACOLOGICAL REVIEWS (2008)
The alliance of sphingosine-1-phosphate and its receptors in immunity
Juan Rivera et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences
EV Loftus
GASTROENTEROLOGY (2004)